*Read Disclaimer Sponsored Content | Unsubscribe
Hello!
New Alert: Vyome Holdings, Inc. (Nasdaq: HIND)
HIND is our brand new NASDAQ under-the-radar alert.
HIND is a newly listed NASDAQ company that just began trading on the exchange in 2025.
The company has a chart setup positioning for a potentially big breakout higher.
Over the past week, HIND has been building what could be a foundation for a substantial rally higher.
In addition, the company has announced multiple developments recently that could serve as big growth catalysts.
HIND is NASDAQ listed "clinical-stage biopharmaceutical company".
HIND is "focused on developing therapies for serious immuno-inflammatory and rare conditions".
HIND is creating a "3-pillar healthcare platform at the intersection of biotech, medical devices, and AI in healthcare".
"Based in Cambridge, MA, Vyome's immediate focus is on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions."
HIND is "building the world's premier platform spanning the US-India innovation corridor".
By applying groundbreaking science and its unique positioning, HIND "seeks to deliver lasting value to shareholders in a cost-efficient manner while upholding global standards of quality and safety".
HIND has "invested millions of dollars to build a portfolio of immuno-inflammatory assets rooted in strong mechanistic science".
Today, the company is focused on "delivering results, with multiple programs advancing toward 12–24 month catalysts that have the potential to create meaningful impact for patients and value for stakeholders".
HIND is advancing treatments in areas of urgent need and low innovation.
Immuno-inflammatory diseases alone "represent a $120B+ market growing rapidly".
Patients with rare or resistant conditions are still underserved.
Here is a look at the company's pipeline:
Malignant Fungating Wounds (MFW) – "Bringing dignity back to late-stage cancer care"
"VT1953 is the first targeted therapy for MFW. Reducing odor, pain, and inflammation through a dual mechanism."
"VT-1953 topical gel is designed to treat the symptoms of MFW by targeting the cause of malodor and inhibiting the drivers of inflammation."
- "Interim Phase 2 Investigator-Initiated Study data demonstrated statistically significant reductions in malodor (P<0.001) — the primary endpoint"
- "Patients also reported reductions in pain and improvements in quality of life"
- "VT-1953 continues to show an excellent safety profile"
- "FDA discussions on pivotal study design and Orphan drug designation are planned for the first half of 2026"
MFW is a debilitating condition that "occurs in 5-14% of advanced cancer patients" where "cancer cells break through the skin and cause a chronic wound (MFW), which is extremely distressing to patients, given the high burden of symptoms."
Sadly, "It is estimated that there are over 693,000 patients with advanced cancer in the US alone and approximately 10M globally."
Uveitis – "A safer and steroid sparing path for Uvetis"
"VT1908, our non-steroidal eye drop, matches steroid performance in preclinical models—without the risks."
Uveitis is the inflammation of a part of the eye, and is "implicated in 30,000 new cases of legal blindness annually, in the United States alone".
"Steroids are the first line of treatment for uveitis, but many patients do not respond, and steroid use causes major complications, including cataract and increased pressure in the eye, leading to glaucoma."
"There is a huge unmet need for a topically administered drug to replace steroid use in the eye."
The company has announced multiple accomplishments since it began trading on the NASDAQ in August.
In September, the company announced:
"Vyome Holdings Acquires MIT AI Spinout Oculo Health"
"The goal is to establish an entirely new therapeutic category at the intersection of mental health, psychoneuroimmunology, and digital health, with global commercialization beginning in the US and India. The team at Oculo has developed an innovative foundation of software and research, including on biomarkers such as 'brain burn' that are quite relevant to our focus at Vyome, and we are excited to build on this foundation," added Pomichter.
In addition:
"The market size for digital therapeutics, especially ones that can reduce the reliance on biologics or other drugs, could end up being greater than $100B over the next decade," said Mohanjit Jolly, a Director at Vyome and Partner at Iron Pillar, a firm with several AI related investments in the US and India. "The advances in AI create an opportunity to use data to better human lives across the board, but our focus is on reducing inflammation in every part of the body. It is one of the biggest health issues facing our society and leads to significant reliance on harmful drugs. I'm excited we were able to close this transaction with Oculo to launch our AI efforts in addition to advancing our existing inflammation-focused biotech assets."
In November, the company announced:
"Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing"
Here are some of the company's comments from this press release:
"Vyome is targeting one of the biggest challenges in the world today - inflammation. So many of our medical and mental problems are linked to increased inflammation. We are building our business with a laser focus on shareholder value, whether it's our capital structure, the development of our assets, or looking at AI opportunities," said Krishna Gupta, Chairman of Vyome. "We had a great first quarter as a public company thanks to our unique strengths, including expertise in/access to the US-India innovation corridor. We announced an important interim result for our drug targeting the billion-dollar opportunity in malignant fungating wound (MFW), and it's just the beginning!"
In addition:
"This quarter marks a defining step forward for Vyome. We executed a highly efficient transition to the public markets, spending less cash than expected in our first quarter as a public company and strengthening our organization while advancing our lead program," noted Venkat Nelabhotla, CEO of Vyome. He further added, "The promising interim Phase 2 results for VT-1953 reinforce the scientific promise of our immuno-inflammation platform. With our disciplined operations, clean capital structure, and world-class team, we are well-positioned to deliver on the milestones ahead and drive long-term value for both shareholders and patients."
In December, the company announced:
"Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval"
Here are the highlights from this press release:
- "VT-1953 treatment over 14 days resulted in highly statistically significant improvements in bad smell or malodor associated with malignant fungating wound (primary endpoint) (P = 0.002)."
- "Patient-reported impact of bad smell or malodor on quality of life (secondary endpoint) improved significantly (P = 0.0256), as did wound pain reduction (P = 0.002)"
- "VT-1953 was well-tolerated, with no new safety concerns observed."
- "Based on these positive Phase 2 results, the company plans to advance VT-1953 into a pivotal study following discussions with the FDA to seek approval to enter $1B potential addressable market opportunity."
Here are some of the company's comments from this press release:
"Venkat Nelabhotla, CEO of Vyome, stated that "these positive results reinforce the potential of VT1953, and we are now preparing to engage with the FDA to design and initiate a pivotal Phase III clinical study in 2026. Over the past several months, we have strengthened our team with top-tier clinical, regulatory, and scientific leaders who bring deep experience in advancing differentiated therapies. This positions us well for disciplined execution as we move into the next phase of development. Vyome remains well capitalized through 2026, allowing us to advance VT1953, a potentially orphan designation program, as a part of our broader chronic immune-inflammation portfolio. We look forward to progressing this program thoughtfully and responsibly toward its next key milestones.""
In addition, the company also announced:
"Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company"
"Born from the prestigious MIT Media Lab, Humanyze has one of the world's largest databases for employee interactions within the workplace and is working to redefine the future of work through science-backed analytics and AI-enabled insights that help large, complex companies make continuous workplace improvements that benefit both employees and the business."
Here are the comments from this press release:
"One of our immediate objectives as the Board of Directors of Vyome was to find a way to create value from LiveChain, as we promised LiveChain and Vyome shareholders. We evaluated multiple options, but this path is the first step of a plan that could enable LiveChain to become self-sufficient financially and build a scalable independent business that could generate significant value for shareholders," commented Venkat Nelabhotla, Board member of LiveChain and CEO of Vyome. "Humanyze is attacking one of the biggest issues facing Fortune 1000 companies around the world – human capital, and the cost of developing, retaining, and rewarding people in the most cost-effective way possible."
In addition:
"Humanyze has built a compelling AI-enabled platform that breaks down critical data to give employers clear, actionable insights that optimize many companies' most valuable resource, their human capital. This optimization is even more critical in an age where humans and AI have to waltz together in the workplace. We see multiple ways for Humanyze to monetize their offerings, and the market opportunity is quite compelling," added Krishna Gupta, Chairman of Vyome.
Two weeks ago, the company announced:
"Independent Analyst Values Vyome's VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study"
Here are the highlights from this press release:
- "Third-party analysis estimates the total addressable U.S. market to be approximately USD 2.2 billion"
- "Modeled peak annual U.S. sales approaching USD 600 million for VT-1953"
- "Independent valuation analysis estimates post-Phase 3 asset value approaching USD 1 billion, and the current valuation with a positive Phase 2 is estimated to be USD 455 million"
Here are some of the comments from this press release:
"Malignant fungating wounds represent one of the most severe and underserved conditions in oncology supportive care," said Tom Filipczak, Managing Director and Partner at Destum Partners. "Our team conducted rigorous primary and secondary research, including clinician interviews, epidemiology modeling, pricing benchmarking, and valuation analyses. Based on the absence of approved therapies and the high unmet need, we believe this indication represents a compelling clinical and commercial opportunity."
Furthermore:
"This independent analysis reinforces our conviction in the potential of VT-1953," said Venkat Nelabhotla, Chief Executive Officer of Vyome. "We engaged a highly experienced third-party consulting firm to conduct a rigorous and unbiased assessment of the commercial opportunity for this program, where there are currently no FDA-approved drugs. Destum Partners' conclusion around the total addressable market in the U.S., together with the modeled potential peak sales and significant post-Phase 3 potential valuation, provides important external validation as we seek to advance VT-1953 toward pivotal development."
On Monday, the company announced:
"Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results"
- "Company Chose Minimal Dilution Path with No Warrants and Has Sufficient Liquidity to Deliver Initial Phase 3 Results for MFW product"
Here are some of the company's comments from this press release:
"We have always been focused on shareholder value and are extremely pleased to report we have successfully funded our most important project's estimated costs until interim findings anticipated in mid-2027," commented Krishna Gupta, Chairman of Vyome. "Inflammation is one of the biggest problems facing the world, and symptoms of MFW are our first target, via VT-1953, in immune-inflammation. As we recently disclosed in an independent valuation report, VT-1953 is estimated by a third party to be worth $1 billion upon anticipated completion of the Phase 3 clinical trials in approximately 18 months. To have achieved this funding at relatively minimal dilution – while turning down funding options at much higher dilution – shows our focus on shareholder value."
In addition:
"In the last week, we were aggressively solicited by multiple investment banks offering larger blocks of capital, but with warrants, investor rights, and other strings attached that we believe would have been harmful to our shareholders," added Venkat Nelabhotla, CEO of Vyome. "Instead, we sourced the absolute lowest cost of capital, with no warrants, and we believe that we are now very well-funded to execute on the plan we have previously laid out to the market on getting VT-1953 through the interim results of Phase 3 clinical trials. We look forward to providing additional updates on our progress soon."
HIND could be positioned for a big breakout higher.
Make sure to do your own due diligence.
Sources: PR1, PR2, PR3, PR4, PR5, PR6, PR7, PR8, PR9, PR10, PR11, Website, Chart
Happy Trading!
AwesomeStocks
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.
